Search results
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks via Yahoo Finance· 1 day agoBristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...
KRAS inhibitors: The next frontier beckons
Pharmaceutical Technology via Yahoo Finance· 1 day agoKRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Therefore, even if the...
Obituary For Eminem’s Alter Ego Slim Shady Published In Detroit Newspaper
HuffPost· 2 days agoThe promotional stunt certainly teases a return to horrorcore for Eminem, whose 2009 effort “Relapse...
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix
Digital Journal· 1 day agoINDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated 123 metastatic ovarian ...
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously...
Benzinga· 22 hours agoThis indication is approved under accelerated approval based on response rate and duration of...
FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe US Food and Drug Administration (FDA) has granted accelerated approval for Bristol Myers...
Q1 2024 Bio Path Holdings Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 1 day agoIt is an open-label, two-stage, multi-center study of prexigebersen in combination with decitabine and venetoclax in two cohorts of patients with previously untreated AML and refractory < ...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 21 hours agoThe regulatory body approved Breyanzi for the treatment of adult patients with relapsed or...
Kirill Vesselov's Resources Unveil New Recovery Features in Boca Raton
Digital Journal· 8 hours agoSkill Development for Relapse Prevention: Focuses on developing coping mechanisms and relapse...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
CBS 47 Fresno· 3 days agoThe Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving ...